Drug Trial Radar · NCT06574568
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Jun 14, 2024
Primary completion
Dec 31, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Excyte Biopharma LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.
Conditions
- Relapsed or Refractory Multiple Myeloma
Interventions
YKST02Drug
BCMA-CD3 bispecific antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose-limiting Toxicities (DLT)Time frame: 21 days after the first dose
- Incidence of Adverse Events (AEs)Time frame: up to 42 weeks
- Incidence of Serious Adverse Events (SAEs)Time frame: up to 42 weeks
- Overall Response Rate (ORR)Time frame: From the date of dosing until the date of first documented progression
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chao-yang Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Beijing Jishuitan Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Shunde Hospital of Southern Medical University
Foshan, Guangdong, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
Affiliated Zhongshan Hospital of Dalian University
Dalian, Liaoning, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
Shanxi Cancer hospital
Taiyuan, Shanxi, China · Not yet recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.